INTRODUCTION
Investigational studies with oncolytic type 5 adenovirus (Ad5), and many other types of oncolytic viruses, have shown few signs of activity when delivered intravenously to human subjects and have struggled to show convincing signs of therapeutic benefit. 1, 2 In contrast, regimens that involve local delivery have provided encouraging results that build a solid foundation for the oncolytic approach. [3] [4] [5] One major reason for poor performance of oncolytic viruses given intravenously likely reflects the hostile environment of the human bloodstream. Most humans possess blood-borne antibodies capable of neutralising many viruses, the result of vaccination or exposure to viruses in the environment, leading to direct neutralisation and allowing fixation of complement. Antibody-independent complement activation in the blood can also inactivate some viruses. 6 In addition, human erythrocytes can prevent Ad5 from infecting target cells by sequestering particles onto the Coxsackie and adenovirus receptor or complement receptor 1, 7 whereas interactions of virus particles with clotting factors 8, 9 and natural antibodies 10 may further modulate infectious activity in vivo. Finally some blood-virus interactions are dependent on the concentration and composition of the blood being used. Although studies using diluted serum or plasma can be useful for reductive mechanistic analyses, assessment of the haemocompatibility of viruses should preferably be performed in undiluted whole human blood rather than relying on dilutions or sub-fractions.
ColoAd1 is an oncolytic group B adenovirus selected from a library of recombinant viruses for its ability to replicate within and exit rapidly from human tumour cells. 11 The genome of ColoAd1 is a chimera of Ad11p and Ad3, but the capsid is derived entirely from Ad11p. ColoAd1 uses CD46 and desmoglein 2 as receptors for cellular infection, 11 whereas Ad5 viruses are thought to use mainly Coxsackie and adenovirus receptor. 7 In comparison to other adenovirus serotypes, the prevalence of neutralising antibodies in the general population to Ad11 is reported to be low 12 which may provide an advantage for systemic delivery. In this brief communication, we compare the activity of ColoAd1 and Ad5 viruses in the presence of human blood components and we develop an assay to measure virus activity in whole human blood, using clinically relevant conditions and virus concentrations.
RESULTS AND DISCUSSION
Comparing the impact of pooled human serum on the activity of ColoAd1 and ONYX-015 We initially assessed the impact of pooled human serum from 11 US normal donors on the ability of ColoAd1 (Ad11p capsid) or ONYX-015 (Ad5 capsid) to kill target tumour cells. Rather than performing a serum titration, we chose to keep the serum concentration fixed and increase the amount of virus particles in order to identify the point of saturation or 'breakthrough' of neutralising activity that would then permit productive infection. Each curve was interpolated to define an IC50, the concentration of virus particles causing 50% killing of cancer cells in our potency assay. In the absence of serum, ColoAd1 showed B50-fold greater potency than Onyx-015. When virus was added to cells in the presence of 20% (vol/vol) human serum, ColoAd1 activity was inhibited o10-fold (shown in Figure 1 by the shift of curves to the right), whereas Onyx-015 activity was inhibited nearly 1000-fold. On the basis of these data it might be expected that oncolytic adenoviruses based on Ad11p would be substantially less prone to neutralisation by human blood than those based on Ad5.
Effects of human blood cells on ColoAd1 activity
We have previously shown that human erythrocytes can bind and sequester Ad5 particles, 7 thereby preventing infection of co-incubated target tumour cells. 13 To assess whether ColoAd1 will be similarly inactivated by blood cells, we incubated the virus with physiological levels of washed human blood cell fraction for 20 min at 37 1C and before conducting cytotoxicity assay on HepG2 cells (Figure 2 ). The data show that blood cells have only a small effect on the IC50 of ColoAd1. This contrasts starkly with our previous observations using Ad5, where human erythrocytes mediated B1000-fold inhibition of infectious activity. 13 Development of an assay to measure virus activity in whole human blood To measure virus activity in whole human blood, a 5-day cytopathicity assay was developed with a cell viability readout measured by MTS reduction. During initial validation using tissue culture medium, results were reproducible between assays with ColoAd1 showing an IC50 range of 0.013-0.056 particles per cell (ppc) and R 2 values between 0.97 and 0.99 fitting against a sigmoidal dose response curve (Figure 3a ). Anticoagulants that chelate calcium can inhibit the complement cascade and even cause some cells to detach from their substrate, confounding haemocompatibility studies. We previously showed that Lithium Heparin does not inhibit complement nor interfere with Ad5 infection 7 and Figure 3a shows that Lithium Heparin also does not inhibit ColoAd1 cytotoxicity, making it suitable for use in the following studies.
Introducing whole human blood into this assay is challenging because of its intrinsic toxicity to epithelial cells, coupled with the difficulty of removing it from monolayers without damaging cells. After method development, we defined an optimal approach where virus is incubated initially in Lithium Heparin-treated whole blood (15 ml for 20 min at 37 1C) before a minimal dilution (by making up to 50 ml) prior to adding to cells. HT29 cell are sufficiently robust for these purposes and are preferable over poorly attached cell types such as 293 and HepG2. Figure 3b shows that HT29 cells survived this protocol when incubated with blood (without virus) from a range of healthy donors, although the introduction of blood components inevitably increases the variability of the assay.
ColoAd1 can kill tumour cells in undiluted whole human blood To assess the ability of human blood to neutralise virus infection, ColoAd1 or Ad5 particles were exposed to samples of Lithium Heparin-treated whole human blood from seven healthy donors. After pre-incubation (20 min, 37 1C) the blood-virus mixture was diluted onto target HT29 cells, cell viability was measured after 5 days and IC50 values were interpolated (Figure 4a) . IC50 values for ColoAd1 in all samples of human blood were greater than in the no-blood control (reflecting attenuation of virus activity). Of the seven samples evaluated, five showed relatively small changes in IC50 values from 0.06 ppc (control) to 0.3-2.2 ppc, whereas two showed larger changes reaching 30 and 156 ppc. The differences between samples may reflect a basal low level of inhibition in most individuals through natural IgMs, cross-reacting IgGs and other interactions, whereas two individuals may have a level of Ad11-specific neutralising antibodies.
Data are represented logarithmically, along the x-axis, as both virus particles per HT29 cell (ppc) and also as the equivalent number of particles per 5L of whole blood. The latter is helpful in determining the 'breakthrough' level of virus needed to achieve bioavailability in human patients, in other words the dose of virus particles required to saturate neutralising activity of the blood. For most individuals breakthrough activity of ColoAd1 occurs at the relatively low concentration of 2 Â 10 6 particles per ml, corresponding to an intravenous (i.v.) dose of 1 Â 10 10 particles per patient (assuming blood volume 5L). Breakthrough in the more neutralising blood samples required 10-100-fold more virus particles, suggesting that at i. In stark contrast, Ad5 did not show appreciable activity in any of the blood samples tested and even the highest virus concentration failed to kill 50% of tumour cells (Figure 4b ). This showed even greater neutralisation than Ad5-based Onyx-015 in the presence of undiluted human serum ( Figure 1 ) and indicates that Ad5-based viruses will be essentially inactive given i.v. even at doses of 1 Â 10 13 virus particles. Higher doses of Ad5 could potentially break through the neutralisation barrier, although particle toxicity and manufacturing feasibility issues make this an unattractive strategy for clinical translation.
Prior to assessing therapeutic activity of viruses given i.v. to patients, it makes sense to ensure that infectivity will not be neutralised immediately following injection. Relying on animal models to predict this is unwise as many blood interactions that are important in humans do not occur in mice. 7 Conventional in vitro blood compatibility assays study the activity of viruses in the presence of individual human blood components (serum or cells, often used in serial dilutions) and these also do not fully model the range of interactions that occurs in undiluted whole blood. 13 Greater clinical relevance can probably be achieved using undiluted human blood and titrating in virus, as shown here, to obtain an idea of the virus dose required to breakthrough neutralisation barriers. This would be of particular value when different geographic populations are known to have different levels of neutralising activity. 14 However, even the use of undiluted whole human blood is still limited by being a closed system, and the impact of clearance mechanisms and the acute phase response should also be considered when predicting clinical bioavailability. Nevertheless, despite these limitations, thoughtful in vitro haematocompatibility studies provide useful insights that should help bridge the gap between laboratory and clinic.
MATERIALS AND METHODS

Cell lines and viruses
Human hepatocellular carcinoma HepG2 and human colon adenocarcinoma HT29 cells were obtained from HPA culture collections and were grown in Dulbecco's modified Eagle's Media (DMEM) containing 2 mM glutamine and 10% FCS. Tissue culture flask and plates were purchased from Corning (Tewksbury, MA, USA). Cells for all studies were seeded in 96-well plates at 10 000 (HepG2) or 30 000 cells/well (HT29) in full growth Figure 3 . Development of cytotoxicity assay using whole human blood: (a) HT29 cells were exposed to a range of ColoAd1 particle concentrations from 0 to 100 ppc in media. After 5 days, the viability was determined by MTS and compared with uninfected controls. Error bars are expressed as s.d., n ¼ 3; 95% confidence intervals, R 2 values and IC50s are shown in the table. Also plotted is a mock blood collection study to determine the impact of anticoagulants whereby media was drawn into a lithium heparin vacuum tube before being used in the assay. This study was performed at the same time as repeat 3. IC50s range from 0.01 to 0.06 and are not significantly different. Part b shows that exposure of HT29 cells for 2 h to 15 ml of human blood made up to 50 ml with normal media does not unduly impact on viability. Donor H data is shown from two separate occasions to demonstrate assay consistency. n ¼ 3; error bars represent 95% confidence intervals. medium 24 h before use. For maintenance post virus infection, DMEM with 2% FCS and 1% penicillin-streptomycin (P/S, PAA, Yeovil, UK) was used. Cell line identity was confirmed by the CRUK Biorepository and cell services core facility in Cambridge. All cell lines are checked for mycoplasma using Mycoalert detection kit (Lonza, Slough, UK) and were free of contamination.
Wild-type adenovirus (Ad5) and dl1520 (E1b55k/E3 deleted, ONYX-015) were kindly provided by Dr Vivien Mautner (University of Birmingham, UK), ColoAd1 was provided by PsiOxus Therapeutics (Abingdon, UK). All viruses were propagated on HEK293 cells and purified twice on CsCl gradients (with intermediate Benzonase treatment) and stored in 50 mM HEPES buffered saline supplemented with 2 mM MgCl 2 and CaCl 2 with 10% glycerol. All reagents were checked for endotoxin using the QCL-1000 kit from Lonza and determined to be o0.1 EU ml À l . Virus concentration (VP ml À l ) was determined using a picogreen assay (Invitrogen, Paisley, UK) calibrated using purified bacteriophage lDNA. Infectious particles were measured by TCID50 on A549 cells at day 7 following fixation with formaldehyde-crystal violet. The P/I ratio (particle/infectious particles) of Ad5 and ColoAd1 are similar, are 35.3 and 34.6, respectively.
Blood collection and handling
Fresh whole blood was collected from healthy donors into Lithiumheparinised tubes (BD, Oxford, UK) within the framework of local ethics approval (C02.217). Blood samples were used immediately for assays (within 1 h). Pooled human serum from 11 donors was purchased from Sera Laboratories, Haywards Heath, UK). All blood products were treated as potentially infectious and were handled in a class II biosafety cabinet and incubator by staff with a full Hepatitis B vaccination.
Serum and blood neutralisation
For studies involving human serum, virus particles were serially diluted 1:3 and added to neat serum (5 ml virus 45ml serum) for 20min at 371C. Forty microlitres of each virus in serum dilution was added to A549 cells growing in a 96-well plate (10 000/well) and made up to 200 ml with maintenance medium and left to incubate in a humidified incubator (37 1C 5% CO 2 ) for 5 days.
For studies involving human blood, virus particles were serially diluted in whole blood samples encompassing a concentration range relevant to i.v. clinical dose levels of 1 Â 10 10 -1 Â 10 13 (2 Â 10 6 -2 Â 10 9 particles per ml assuming 5L of blood). Samples were mixed thoroughly and incubated for 20 min at 37 1C. Fifteen microlitres of blood sample was then added to HT29 cells in 96-well plates (30 000 cells per well) and made up to 50 ml with maintenance medium and incubated at 37 1C. After 2 h, the cells were washed with saline (5 Â ), refreshed with maintenance media and incubated for 5 days.
Cell viability assay
To analyse viability, cells were washed with PBS twice and placed in fresh DMEM without phenol red media (2% FCS, 1% P/S). MTS reagent (20 ml, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) was then added (cellTiter 96 aqueous non-radioactive cell proliferation assay, Promega, Southampton, UK). After 1 h, absorbance was read using a microplate reader at 490 nm (Wallac Victor 1420, Perkin Elmer, Cambridge, UK). The reading of mock-treated cells served as negative controls and established 100% survival point for the given assay, and the reading of the medium alone with MTS reagent was used as a zero point. Cytotoxicity curves were analysed with Graphpad Prism software (GraphPad Inc., La Jolla, CA, USA) and fitted to a sigmoidal dose response curve (variable slope).
